Abstract
Apoptosis of bronchial epithelial cells and the phagocytic clearance of these cells by alveolar macrophages (a process termed efferocytosis) are integral processes leading to repair of airway epithelial injury. Efferocytosis allows for the removal of apoptotic material with minimal inflammation and prevents the development of secondary necrosis and ongoing inflammation. Defective efferocytosis and the increased presence of apoptotic cells have been identified in the airways of subjects with chronic obstructive pulmonary disease (COPD). There are three major potential causes for this accumulation of apoptotic cells: (i) increased apoptosis per se as a result of an increase in apoptotic mediators, (ii) defects in the recognition of apoptotic cells by AM and (iii) failure to clear the unwanted cells by the process of efferocytosis. The implications of these processes in COPD and novel treatment strategies aimed at improving clearance of apoptotic cells form the focus of the present review.
Keywords: Alveolar macrophage, apoptosis, collectin, COPD, efferocytosis, phagocytosis, tobacco smoke, protease, granzyme, perforin, oxidative stress, Mannose receptor
Current Drug Targets
Title: Airway Clearance of Apoptotic Cells in COPD
Volume: 12 Issue: 4
Author(s): Violet R.S. Mukaro and Sandra Hodge
Affiliation:
Keywords: Alveolar macrophage, apoptosis, collectin, COPD, efferocytosis, phagocytosis, tobacco smoke, protease, granzyme, perforin, oxidative stress, Mannose receptor
Abstract: Apoptosis of bronchial epithelial cells and the phagocytic clearance of these cells by alveolar macrophages (a process termed efferocytosis) are integral processes leading to repair of airway epithelial injury. Efferocytosis allows for the removal of apoptotic material with minimal inflammation and prevents the development of secondary necrosis and ongoing inflammation. Defective efferocytosis and the increased presence of apoptotic cells have been identified in the airways of subjects with chronic obstructive pulmonary disease (COPD). There are three major potential causes for this accumulation of apoptotic cells: (i) increased apoptosis per se as a result of an increase in apoptotic mediators, (ii) defects in the recognition of apoptotic cells by AM and (iii) failure to clear the unwanted cells by the process of efferocytosis. The implications of these processes in COPD and novel treatment strategies aimed at improving clearance of apoptotic cells form the focus of the present review.
Export Options
About this article
Cite this article as:
R.S. Mukaro Violet and Hodge Sandra, Airway Clearance of Apoptotic Cells in COPD, Current Drug Targets 2011; 12 (4) . https://dx.doi.org/10.2174/138945011794751609
DOI https://dx.doi.org/10.2174/138945011794751609 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interstitial Lung Disease in Rheumatoid Arthritis
Current Rheumatology Reviews Aptamers Biosensors for Pharmaceutical Compounds
Combinatorial Chemistry & High Throughput Screening Neonatal Fever in the Term Infant: Evaluation and Management Strategies
Current Pediatric Reviews Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Ivabradine for Treatment of Coronary Artery Disease: From Last Chance Resort to Mainstem of a Reasoned Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Brain Protection and Cognitive Function: Cocoa Flavonoids as Nutraceuticals
Current Pharmaceutical Design Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
Current Drug Targets Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Tamoxifen as a Powerful Neuroprotectant in Experimental Stroke and Implications for Human Stroke Therapy
Recent Patents on CNS Drug Discovery (Discontinued) How Should Serum Uric Acid Concentrations be Interpreted in Patients with Hypertension?
Current Hypertension Reviews Patent Selections
Recent Patents on Biotechnology Profiling the Shear Stress of Atherosclerosis; A Genomic View
Current Genomics Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology NAD+, Sirtuins, and Cardiovascular Disease
Current Pharmaceutical Design Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry Treasures Hunt in Old Mines: Terminalia chebula-Based Traditional Herbal Medicinal Products
The Natural Products Journal Editorial [Hot topic: New Developments in the Treatment and Prevention of Vascular Disease - Part 1 (Executive Editors: N. Katsiki, V.G. Athyros and D.P. Mikhailidis)]
Current Pharmaceutical Design Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy